HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Adler, C. H. Articles by Hentz, J. G. Search for Related Content PubMed PubMed Citation Articles by Adler, C. H. Articles by Hentz, J. G. Related Collections All Clinical trials Clinical trials Randomized controlled (CONSORT agreement) Restless legs syndrome

Ropinirole for restless legs syndrome

A placebo-controlled crossover trial

From the Parkinson’s Disease and Movement Disorders Center (Drs. Adler and Caviness, L. Marlor), Department of Neurology, and Department of Biostatistics (J.G. Hentz), Mayo Clinic Scottsdale, AZ; Departments of Neurology, Pharmacology, and Experimental Therapeutics (Dr. Hauser) and Internal Medicine (Dr. Anderson), University of South Florida, Tampa; and Department of Neurology (Dr. Sethi), Medical College of Georgia, Augusta.

Address correspondence and reprint requests to Dr. C.H. Adler, Parkinson’s Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Blvd., Scottsdale, AZ 85259; e-mail: cadler{at}mayo.edu

The authors performed a double-blind, placebo-controlled, crossover study of ropinirole (0.5 to 6.0 mg/day) for restless legs syndrome (RLS). The RLS Rating Scale score improved (p < 0.001) from a mean (SD) of 25 (7) during placebo treatment to 13 (12) during ropinirole treatment. Eight of the 22 patients had complete resolution of symptoms on ropinirole. Adverse events included nausea and dizziness. Ropinirole was effective and well tolerated for treating the symptoms of RLS.

Received August 7, 2003. Accepted in final form December 23, 2003.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 27 issue to find the title link for this article.

Drs. Adler, Anderson, Hauser, and Sethi have served as consultants to GlaxoSmithKline. Drs. Adler and Sethi have received compensation in excess of $10,000.

Presented at the American Academy of Neurology Meeting, Honolulu, HI, April 2003.

This article has been cited by other articles:

				W. L. Baker, C. M. White, and C. I. Coleman Effect of Nonergot Dopamine Agonists on Symptoms of Restless Legs Syndrome Ann. Fam. Med, May 1, 2008; 6(3): 253 - 262. [Abstract] [Full Text] [PDF]

				S. Fulda and T. C. Wetter Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies Brain, April 1, 2008; 131(4): 902 - 917. [Abstract] [Full Text] [PDF]

				M. Ryan and J. T. Slevin Restless Legs Syndrome Journal of Pharmacy Practice, December 1, 2007; 20(6): 430 - 448. [Abstract] [PDF]

				M. Ryan and J. T. Slevin Restless legs syndrome. Am. J. Health Syst. Pharm., September 1, 2006; 63(17): 1599 - 1612. [Abstract] [Full Text] [PDF]

				Other articles noted Evid. Based Med., September 1, 2004; 9(5): e5 - e5. [Full Text] [PDF]

				M. H. Silber, B. L. Ehrenberg, R. P. Allen, M. J. Buchfuhrer, C. J. Earley, W. A. Hening, D. B. Rye, and Medical Advisory Board of the Restless Legs Syndro An Algorithm for the Management of Restless Legs Syndrome Mayo Clin. Proc., July 1, 2004; 79(7): 916 - 922. [Abstract] [PDF]